Up to 15 percent of children and five percent of adults are affected by the chronic inflammatory skin disease atopic dermatitis. Despite advanced therapy measures, the severe itching… read more.
Two phase 3 trials suggest that a 16 week treatment with a drug called lebrikizumab was effective in adults and adolescents with moderate to severe dermatitis, according to… read more.
For children and young people, skin disorders can have a devastating impact on physical and mental wellbeing, yet effective treatments are few and far between. That’s why the… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
